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Abstract
Human cancer is caused by the interplay of mutations in oncogenes and tumor suppressor
genes and inherited variations in cancer susceptibility genes. While many of the tumor initiat-
ing mutations are well characterized, the effect of genetic background variation on disease
onset and progression is less understood. We have usedC. elegans genetics to identify ge-
netic modifiers of the oncogenic RAS/MAPK signaling pathway. Quantitative trait locus analy-
sis of two highly divergedC. elegans isolates combined with allele swapping experiments
identified the polymorphic monoamine oxidase A (MAOA) gene amx-2 as a negative regulator
of RAS/MAPK signaling. We further show that the serotonin metabolite 5-hydroxyindoleacetic
acid (5-HIAA), which is a product of MAOA catalysis, systemically inhibits RAS/MAPK signal-
ing in different organs ofC. elegans. Thus, MAOA activity sets a global threshold for MAPK
activation by controlling 5-HIAA levels. To our knowledge, 5-HIAA is the first endogenous
small molecule that acts as a systemic inhibitor of RAS/MAPK signaling.
Author Summary
Mutations that activate a RAS oncogene are found in a large proportion of human cancers.
In this study, we have used the roundworm Caenorhabditis elegans (C. elegans) as a model
to investigate how the genetic composition of the animal affects the outcome of oncogenic
RAS mutations that activate the MAPK pathway. By comparing the effects of activated
RAS/MAPK signaling in two genetically different C. elegans strains, we have identified the
monoamine oxidase A (MAOA) gene amx-2 as a negative regulator of RAS/MAPK signal-
ing. MAOA enzymes are primarily known to catalyze the degradation of the neurotrans-
mitters dopamine and serotonin. Here, we show that a specific serotonin degradation
product that is produced by MAOA (5-HIAA) inhibits RAS signaling in different organs
of C. elegans. Thus, by producing the inhibitory serotonin metabolite 5-HIAA the MAOA
enzyme systemically controls the activation of the RAS/MAPK pathway.
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Introduction
Human cancer is a complex polygenic disease caused by somatic mutations in oncogenes and
tumor suppressor genes together with inherited polymorphisms in cancer susceptibility genes.
Many of the oncogenes and tumor suppressor genes that are mutated in different cancer types
have been investigated in detail. However, relatively little is known about the effect of the ge-
netic background on disease onset and progression. It thus remains a challenge to identify
functional links between oncogenic traits and associated natural variants [1,2].
The components of the RAS/MAPK signaling pathway are mutated in a large fraction of
human tumors. In particular, activating (“gain-of-function”) mutations in HRAS and KRAS
are among the most prevalent tumor initiating mutations found in human cancer cells [3].
Thanks to the strong conservation of this pathway in metazoans, genetic studies in model or-
ganisms, such as the nematode Caenorhabditis elegans, have provided important insights into
various factors modulating RAS/MAPK signaling [4]. Moreover, C. elegans has become a plat-
form species for quantitative genetic analyses of various phenotypes and pathways in order to
identify and characterize polymorphic genes [5,6]
In this study, we have used quantitative genetics to explore how the genetic background af-
fects the phenotypes caused by the activating G13E (n1046) mutation in the C. elegans ras gene
let-60 [7]. The n1046mutation is homologous to the HRAS and KRAS mutations that are fre-
quently found in human cancer cells [3]. For the purpose of this study, we compared RAS/
MAPK signaling in two highly diverse genetic backgrounds, C. elegans varieties Bristol (N2)
and Hawaii (CB4856) [8]. Compared to the reference strain N2, the Hawaiian CB4856 strain
on average contains one polymorphism every 412 bp with around 75% of all genes carrying at
least one coding polymorphism [9].
To measure the activity of the RAS/MAPK pathway in different genetic backgrounds, vulval
induction can be used as a quantifiable and reproducible readout. During vulval development,
the anchor cell in the somatic gonad secretes the EGF-like ligand that activates via an EGFR
family receptor tyrosine kinase the RAS/MAPK signaling pathway in the adjacent vulval pre-
cursor cells (VPCs) [10]. In combination with a lateral NOTCH signal, RAS/MAPK signaling
induces three of the six VPCs to adopt a 2°-1°-2° pattern of vulval cell fates (Fig 1A). Mutations
that hyperactivate RAS/MAPK signaling, such as the n1046 allele, cause the differentiation of
more than three and up to six VPCs and a Multivulva phenotype, while mutations that reduce
RAS/MAPK signaling result in the induction of fewer than three VPCs and a Vulvaless pheno-
type. Hence, the average number of induced VPCs per animal, the vulval induction (VI), is a
quantitative measure of RAS/MAPK signaling output in the VPCs [10,11]. Besides the vulva,
RAS/MAPK signaling is activated in a variety of other tissues in C. elegans at different develop-
mental stages, such as the meiotic germ cells in the hermaphrodite gonads, the excretory duct
cell precursor in the embryo or the chemosensory neurons during olfaction in adults [4]. Using
a quantitative genetics approach, we aimed at identifying globally acting as well tissue-specific
modifiers of RAS/MAPK signaling. Here, we describe the identification of the polymorphic
monoamine oxidase amx-2 gene as a global negative regulator of the RAS/MAPK pathway.
amx-2 encodes a mitochondrial monoamine oxidase type A (MAOA) that catalyzes the oxida-
tive deamination of biogenic amines such as dopamine (DA) and serotonin (5-HT) [12]. We
further show that AMX-2 activity in intestinal cells controls the levels of the serotonin metabo-
lite 5-hydroxyindoleacetic acid (5-HIAA), which acts as systemic inhibitor of
MAPK phosphorylation.
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Results
Identification of RAS/MAPKmodifiers by quantitative C. elegans
genetics
To identify polymorphic modifiers of the RAS/MAPK pathway, we generated a set of 228 “mu-
tation included recombinant inbred lines” (miRILs) between the Bristol strain MT2124 that
carries the activating let-60 ras(n1046gf)mutation [7] and the Hawaiian CB4856 strain (Fig
1B). Since small genetic variations are efficiently buffered in a wild-type genome [13,14], the
Fig 1. QTLmapping of let-60 rasmodifiers. (A) RAS/MAPK signaling induces three VPCs. P6.p receives most of the inductive EGF signal from the anchor
cell and activates the EGFR/RAS/MAPK pathway inducing the 1° cell fate (green arrows). Lateral signaling via the Notch pathway induces the 2° cell fate in
the neighboring VPCs P5.p and P7.p (red arrows). The remaining VPCs (blue) adopt the non-vulval 3° cell fate. (B) Crossing scheme to generate the let-60
(n1046gf)miRILs. Hawaii males (red) were crossed with Bristol let-60(n1046gf)mutants (blue). For each example animal, the two chromosomes IV carrying
the n1046mutation and another arbitrary chromosome pair are shown. Random segregation of the two parental genomes was allowed except for the let-60
(gf)mutation that was kept homozygous from F2 generation onwards. After ten generations of self-fertilization to drive all regions to homozygosity, 228
independent miRILs were obtained. (C)Genotypes and phenotypes of the let-60(gf)miRILs sorted by increasing VI. Genotypes determined by FLPmapping
[15] are plotted on the y-axis versus the miRIL numbers on the x-axis. Hawaii genotypes are indicated with red, Bristol genotypes with blue and missing
genotypes with gray colors. The VIs for each miRIL are shown below the genotypes. Error bars indicate the standard error of the mean. (D)QTLmapping
identified three regions (QTL1 through QTL3) above the threshold LOD score of 3 (dotted red line). In each of the panels showing chromosomes I through X,
the locations of the FLPmarkers used for genotyping are indicated on the x-axis with vertical lines. For the exact locations of the FLPs used, see Materials
and Methods and [15].
doi:10.1371/journal.pgen.1005236.g001
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inclusion of the let-60(gf) allele created a sensitized genetic background, allowing us to identify
genetic modifiers that increase or decrease RAS/MAPK signaling. After 10 generations of in-
breeding and genotyping using fragment length polymorphisms (FLPs) [15], 173 of the miRILs
homozygous for the n1046 allele were used for further analysis (Fig 1C, top) (see Materials and
Methods for details on genotyping and the selection of informative miRILs). In addition, we
quantified RAS/MAPK signaling output in each of these miRILs by measuring the VI of at least
20 animals. While the let-60(gf) allele in the Bristol background exhibits a VI of 3.7±0.06
(n = 100), the VIs of the miRILs varied between 3.0 and 5.7 (Fig 1C, bottom). Quantitative
trait loci (QTL) mapping [14] identified at least three loci on chromosomes I (QTL1), II (QTL
2) and V (QTL 3) above the threshold LOD score of 3 that are associated with variation in the
VI (Fig 1D). For QTL1, the Bristol genotype is associated with a decreased VI, while for QTL2
and QTL3 the Bristol genotype is associated with an increased VI (S1 Fig). To estimate the ef-
fect size of each QTL and explore how the QTLs affect the VI when combined, we used two
mapping models, one where the QTLs have additive effects and another one where they show
an interaction (S1 Table). This analysis did not detect any significant interactions between the
QTLs. Since the let-60(gf)mutation maps to chromosome IV, our approach did not permit us
to identify QTLs on this chromosome. Moreover, the genetic incompatibility between the Bris-
tol and Hawaii genomes caused by the zeel-1 and peel-1 loci on the left arm of chromosome I
may have prevented the detection of QTLs in this region [16]. To confirm and refine the map-
ping of the detected QTLs, introgression lines (ILs) carrying defined segments of the Hawaii
genome in the QTL regions of interest were crossed to the let-60(gf) Bristol strain [17]. Lines
homozygous for the introgressions and the let-60(gf)mutation were compared to sibling lines
without introgressions to identify those introgressions that cause significant differences in the
VI (see Materials and Methods). The results for the fine mapping of QTL1 are shown in Fig 2A
and for all QTLs in S2 Fig IL mapping revealed that QTL1 is composed of two adjacent QTLs,
termed 1a and 1b, and that QTL1b maps to an interval of 1.43 Mbp containing 142 polymor-
phic genes (Fig 2A). Through this approach, we have identified several regions in the C. elegans
genome that contain modifiers of the RAS/MAPK pathway. Notably, for QTL1a and QTL1b
the Bristol genotype caused reduced RAS/MAPK activity, while for QTL2 and QTL3 the Bristol
background increased RAS/MAPK activity.
The polymorphic amx-2 gene negatively regulates RAS/MAPK signaling
Since the QTL1b region does not contain any known regulators of RAS/MAPK signaling, we
performed RNAi knockdown of 107 of the 142 genes in this region in let-60(gf) single mutants
as well as in let-60(gf)mutants carrying the ewIR17 introgression, which spans QTL1b. We en-
visioned two possible scenarios that are not mutually exclusive: (1) The QTL1b region in the
Bristol strain may contain a negative regulator of RAS/MAPK signaling that is inactive or
weakly active in the Hawaii background. (2) The Hawaii background may contain a positive
regulator of RAS/MAPK signaling that is inactive or weakly active in the Bristol background.
We thus screened for candidates exhibiting allele-specific RNAi effects (S2 Table). Note that
when grown on the E.coli strain HT115 that is commonly used in RNAi feeding experiments
[18], the let-60(n1046) allele exhibits an increased VI compared to animals grown on standard
OP50 bacteria [19]. Knockdown of five genes significantly increased the VI in the let-60(gf) but
not in the ewIR17; let-60(gf) background, defining potential negative regulators of RAS/MAPK
signaling that are active in the Bristol background (highlighted in green in S2 Table), whereas
knockdown of ten genes reduced the VI in the ewIR17; let-60(gf) but not in the let-60(gf) back-
ground, defining potential positive regulators active in the Hawaii background (highlighted in
blue in S2 Table). These data suggested that the QTL1b region is oligogenic, containing several
Systemic Regulation of RAS/MAPK Signaling
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polymorphic modifiers of RAS/MAPK signaling. Of particular interest was the amx-2 gene be-
cause it fulfilled the criteria of a polymorphic negative regulator of RAS/MAPK signaling acting
in the Bristol strain, but being inactive in the Hawaii strain. amx-2 RNAi had no significant ef-
fect on the ewIR17; let-60(gf) background, but amx-2 RNAi caused a robust increase in the VI
of let-60(gf)mutants (Fig 2B). Furthermore, the amx-2(ok1235) deletion mutant, which most
likely represents a null allele (www.wormbase.org), increased the VI of let-60(gf)mutants in the
Bristol background (Fig 2C). To individually assess the activities of the Bristol and Hawaii
amx-2 variants, we generated single-copy insertions on chromosome II [20] of a 7.8 kb geno-
mic fragment spanning the amx-2 locus that was isolated either from the Bristol or the Hawaii
genome. These single-copy transgenes were then introduced (homozygously) into the amx-2
(lf); let-60(gf) background. Insertion of the Bristol but not the Hawaii amx-2 variant reduced
Fig 2. AMX-2 negatively regulates RAS/MAPK signaling. (A) Fine-mapping of QTL1 with ILs. For each IL, the regions containing the Hawaii (black)
genome in the Bristol (grey) background are indicated, and the corresponding VIs are plotted below. Black columns indicate the average VI of three
independent lines carrying an introgression and gray columns the average VI of three sibling lines without introgression. Dashed boxes indicate the QTL1a
and QTL1b sub-regions. (B) Allele-specific effects of amx-2RNAi compared to empty vector controls. (C) Two copies of Bristol but not Hawaii amx-2 rescue
the increased VI of amx-2(ok1235); let-60(n1046gf) double mutants. (D) Epistasis analysis of amx-2(ok1235). The dashed line indicates the wild-type VI of 3.
(E-H) Expression pattern of a transcriptional Pamx-2::gfp reporter in the pharynx and head neurons (E), the adult vulva (F), the intestine (G) and some rectal
cells (H) of L4 larvae. The scale bar is 10μm. (I) Tissue-specific amx-2RNAi. Knock-down in the intestine but not the vulval cells increases the VI of let-60
(n1046gf)mutants (J)Quantitative PCR of amx-2 and amx-1. Expression levels were normalized to the N2 wild-type Bristol strain. Error bars in (A) to (I)
indicate the standard error of the mean and in (J) the standard deviation measured in three independent experiments. The numbers of animals scored are
shown inside the columns. *** indicates p<0.001, ** p<0.01, *<0.05 and n.s. p>0.1 in a Student’s t-test.
doi:10.1371/journal.pgen.1005236.g002
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the VI of amx-2(lf); let-60(gf) double mutants to the value observed in let-60(gf) single mutants
(Fig 2C). These results confirmed the different physiological activities of the two amx-2 vari-
ants. In addition, amx-2(lf) partially suppressed the Vulvaless phenotype caused by reduction-
of-function mutations in let-60 ras [7] or the EGFR homolog let-23 [10] and enhanced the
Multivulva phenotype of the let-23 gain-of-function mutation sa62 [21] (Fig 2D). We thus
conclude that the Bristol variant of the amx-2 gene inhibits RAS/MAPK signaling in the VPCs.
amx-2 in intestinal cells inhibits RAS/MAPK signaling cell non-
autonomously
To determine the site of amx-2 action, we generated transcriptional Pamx-2::gfp reporters. amx-
2 was expressed in head neurons, the intestine and in a subset of cells of the rectum and in the
adult vulva (Fig 2E–2H). However, we did not observe any amx-2 expression in the VPCs dur-
ing vulval induction, though amx-2 reporter levels could be below the detection limit. Since
neurons have a low sensitivity to RNAi [22], yet amx-2i efficiently phenocopied the amx-2(lf)
phenotype, we suspected that amx-2might act in intestinal cells, where we detected strongest
expression. Intestine-specific amx-2 RNAi using an rde-1(lf); let-60(gf); Pelt-2::rde-1(+) strain
[23] increased the VI to a similar degree as systemic RNAi, while vulva-specific RNAi using the
Plin-31::rde-1(+) transgene [24] had no detectable effect, which is consistent with lack of detect-
able amx-2 reporter expression in the VPCs (Fig 2I, note that the overall lower VI in the vulva-
specific RNAi strain is due to the genetic background [24]). Taken together, AMX-2 most likely
acts in the intestinal cells to negatively regulate RAS/MAPK signaling in the VPCs.
Expression of amx-1 is increased in amx-2(lf)mutants
To investigate a possible redundancy between the MAOA amx-2 and the MAOB gene amx-1,
we measured the transcript levels of amx-2 and its paralog amx-1 by quantitative real-time
PCR. The abundance of amx-2 and amx-1 transcripts was not significantly different between
the Bristol and Hawaii backgrounds (Fig 2J). However, amx-2 transcript levels were around
60% decreased and amx-1 levels around 40% increased in amx-2(lf)mutants. Possibly, the ele-
vated amx-1 expression can partially compensate for a loss of amx-2 expression.
The 5-HT metabolite 5-HIAA acts as systemic inhibitor of RAS/MAPK
signaling
amx-2 encodes a member of the mitochondrial monoamine oxidase (MAO) family [25]. Se-
quence alignments of the catalytic domains of different MAOs indicated that AMX-2 is most
closely related to the ancestor of the mammalian MAOA, MAOB and L-amino oxidases (S3
Fig). The Hawaii AMX-2 variant possesses two coding polymorphisms in the catalytic domain
(V410I and N461S) and another four in the C-terminal region (R521G, T532S, N535S and
L617P) (S4 Fig). MAOs are key enzymes in the degradation of the neurotransmitters 5-HT
and DA (Fig 3A) [12]. The products of the DA and 5-HT deamination reactions, 3,4-dihydrox-
yphenylacetaldehyde and 5-hydroxyindole-acetaldehyde respectively, are further oxidized by
aldehyde dehydrogenases into 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid
(5-HIAA), which in humans are secreted through the kidneys (Fig 3A) [26]. Consistent with
the predicted function of AMX-2 in degrading 5-HT, total extracts of amx-2(lf) worms con-
tained elevated levels of 5-HT when compared to wild-type extracts (Fig 3B).
We thus investigated if AMX-2 inhibits RAS/MAPK signaling by controlling the levels of
DA, 5-HT or their metabolites. The addition of 10mM DA to the growth medium had no sig-
nificant effect on the VI of let-60(gf) single or amx-2(lf); let-60(gf) double mutants (Fig 3C).
Systemic Regulation of RAS/MAPK Signaling
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However, 1mM 5-HT as well as 1mM of the 5-HT metabolite 5-HIAA caused a strong reduc-
tion of the VI in both backgrounds and a suppression of the Multivulva phenotype (Fig 3C
and 3D). Addition of 0.6mMmelatonin (MT), another 5-HT metabolite (Fig 3A), had a slight-
ly weaker yet significant effect on the VI (Fig 3C). We conclude that the 5-HT metabolites, in
particular 5-HIAA, inhibit RAS/MAPK signaling. To test the sensitivity of the RAS/MAPK
pathway to 5-HT and 5-HIAA, we performed dose-response experiments in the presence and
absence of amx-2. For both compounds, the maximum reduction of the VI was observed at
concentrations above 1mM (Fig 3E and 3F). However, let-60(gf) single mutants displayed a
higher sensitivity to low concentrations (1μM) of 5-HT than amx-2(lf); let-60(gf) double mu-
tants, while the effects of 5-HIAA were independent of the amx-2 genotype. Overall, 5-HT ex-
erted a slightly stronger effect than 5-HIAA, suggesting that additional 5-HT metabolites
besides 5-HIAA may inhibit RAS/MAPK signaling.
To determine at which step 5-HIAA regulates the RAS/MAPK pathway, we examined a
strain expressing an activated form of the MAPKMPK-1 along with the MAPKKMEK-2 [27]
(mpk-1(gf)). Application of 4mM 5-HIAA did not alter the VI ofmpk-1(gf)mutants (Fig 3G).
Also, 5-HIAA did not affect a lfmutation in lin-1, which encodes an ETS family transcription
factor that represses vulval induction downstream of MPK-1 [28] (Fig 3G). Taken together,
these results indicate that 5-HIAA inhibits RAS/MAPK signaling upstream of MPK-1.
5-HIAA acts via the 5-HT receptor SER-1 and the EGL-30 Gqα pathway
We further characterized the inhibitory effect of 5-HIAA on the RAS/MAPK pathway by test-
ing mutants in the 5-HT pathway for their response to 5-HIAA treatment. A mutation in the
tryptophan hydroxylase gene tph-1, which is essential for 5-HT biosynthesis [29], slightly re-
duced the VI in let-60(n1046gf) animals in the absence of 5-HIAA (Fig 3H). However, treat-
ment of tph-1(lf); let-60(n1046gf) double mutants with 4mM 5-HIAA further reduced the VI,
indicating that 5-HIAA acts in the absence of endogenous 5-HT and hence does not compete
with 5-HT. By contrast, the VI of let-60(n1046gf) animals carrying a mutation in the 5-HT re-
ceptor gene ser-1 [30] was not reduced by 5-HIAA treatment. Surprisingly, the VI of let-60(gf);
ser-1(lf) double mutants was even increased after 5-HIAA treatment. Moreover, a gain-of-func-
tion mutation in egl-30, which encodes a Gqα protein acting in the 5-HT pathway [31], ren-
dered let-60(n1046gf)mutants resistant to 5-HIAA and caused a slight increase of the VI in
untreated animals (Fig 3H). Since the SER-1/EGL-30 pathway plays an essential role in 5-HT
stimulated egg laying [30], we tested the effects of 5-HIAA on the egg laying rate with and
without 5-HT stimulation. While 5-HIAA treatment alone caused a slight reduction in the egg
laying rate, 5-HIAA did not significantly compete with the 5-HT stimulated increase in egg lay-
ing (S5 Fig). We conclude that 5-HIAA acts via the SER-1 receptor and the downstream EGL-
30 Gqα signaling pathway to repress RAS/MAPK activity. However, the inhibitory effect of
5-HIAA is independent of 5-HT activity.
Fig 3. Systemic inhibition of RAS/MAPK signaling by Serotonin and its metabolites. (A) Function of MAOA in DA and 5-HT degradation. (B) 5-HT
levels in total extracts of wild-type and amx-2(ok1235) animals. (C) Effect of DA, 5-HT and its metabolites on the VI of let-60(n1046gf) single and amx-2
(ok1235); let-60(n1046gf) double mutants. (D) Examples of (top) a 5-HIAA treated and (bottom) an untreated let-60(n1046gf) L4 larva. The normal vulva and
the ectopically induced cells are underlined. (E) Dose-dependent reduction of the VI by 5-HT and (F) 5-HIAA treatments. Note in (E) the different sensitivities
of the two strains to 1μM 5-HT. (G) Effect of 5-HIAA on mutations activating the EGFR/RAS/MAPK pathway at different levels. (H) Resistance of some 5-HT
pathway mutants to 5-HIAA treatment. Error bars indicate the standard error of the mean. The numbers of animals scored are indicated in brackets or inside
the columns. *** indicates p<0.001, ** p<0.01, and n.s. p>0.1 in a Student’s t-test.
doi:10.1371/journal.pgen.1005236.g003
Systemic Regulation of RAS/MAPK Signaling
PLOS Genetics | DOI:10.1371/journal.pgen.1005236 May 15, 2015 8 / 16
5-HIAA attenuates RAS/MAPK signaling in multiple organs of C. elegans
Besides the VPCs, RAS/MAPK signaling is required in several other organs of C. elegans [4].
Hence, let-60(gf)mutants exhibit multiple defects besides a Muv phenotype. For example, the
temperature-sensitive let-60(ga89gf) allele causes accelerated exit of meiotic germ cells from the
pachytene stage, resulting in the accumulation of many immature oocytes in the proximal
gonad arm at the restrictive temperature [32,33] (Fig 4A). Moreover, let-60(n1046gf)mutants
frequently contain two duct cells expressing the lin-48::gfpmarker [34] (Fig 4B). Treatment
with 4mM 5-HIAA partially suppressed the let-60(gf) phenotypes both in the germ line and the
duct cell (Fig 4A and 4B). To measure the global effect of 5-HT and 5-HIAA treatment on
Fig 4. 5-HIAA inhibits RAS/MAPK signaling and MPK-1 phosphorylation in multiple organs ofC. elegans. (A) Partial suppression of the germline
defect in let-60(ga89ts)mutants treated with 5-HIAA and grown at 25°C. The images show the gonads of 5-HIAA treated (top) and untreated (bottom) young
adults. Note the regularly stacked oocytes in 5-HIAA treated and the irregularly stacked and smaller oocytes in untreated animals. (B) Partial suppression of
the duct cell duplication phenotype in let-60(n1046gf)mutants by 5-HIAA. The images show the single duct cell in a 5-HIAA treated let-60(n1046gf) L4 larva
(top) and the two duct cells in an untreated larva (bottom). The arrows point at the nuclei of the duct cells expressing the lin-48::gfpmarker. (C)MPK-1
phosphorylation in total extracts of let-60(n1046gf) single and amx-2(ok1235); let-60(n1046gf) double mutant larvae treated with 4mM 5-HT or 5-HIAA. The
ratios of phosphoMPK-1 to total MPK-1 levels were determined in three independent experiments as described in [11] and Materials and Methods. Values
were normalized to the ratios in untreated animals. The numbers of animals scored are indicated in brackets or inside the columns. *** indicates p<0.001
and ** p<0.01 in a Student’s t-test
doi:10.1371/journal.pgen.1005236.g004
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MAPK activation, we quantified the levels of activated, phosphorylated MPK-1 in total extracts
of L4 larvae [11]. Treatment with 5-HT and 5-HIAA caused a similar reduction in phospho-
MPK-1 levels in let-60(gf)mutants. However, in the amx-2(lf); let-60(gf) background 5-HIAA
exerted a stronger effect than 5-HT (Fig 4C). Thus, 5-HIAA supplemented into the culture me-
dium exerts a systemic effect to inhibit RAS/MAPK signaling in different organs of C. elegans.
Discussion
We have identified several genetic modifiers of the oncogenic RAS/MAPK signaling pathway
by comparing miRILs derived from the backgrounds of two highly diverged C. elegans isolates.
The two parental strains used in this study display a level of sequence divergence that is compa-
rable to the genetic variation observed in the human population [35]. The genetic modifiers of
RAS/MAPK signaling we identified through this quantitative approach could not have been
found in conventional forward genetic screens, as each locus alone only exerts a minor effect.
Interestingly, both genetic backgrounds analyzed contain QTLs that enhance (i.e. QTLs 2 and
3 for Bristol) as well as QTLs that reduce (i.e. QTL 1 for Bristol) the relative strength of RAS/
MAPK signaling. Thus, each isogenic background may represent a balanced state exhibiting in-
termediate RAS/MAPK pathway activity thanks to the opposing effects of the different modifi-
ers. The interplay of these modifiers may be necessary to keep the activity of the RAS/MAPK
pathway within a certain range and avoid the detrimental effects caused by increased or re-
duced RAS/MAPK signaling.
The molecular characterization of one particular region (QTL 1b) identified the monoamine
oxidase gene amx-2 as a negative regulator of RAS/MAPK signaling in multiple organs of C.
elegans. Though, the RNAi analysis of the QTL1b region indicated that this region contains
possibly up to ten additional polymorphic modifiers of RAS/MAPK signaling besides amx-2.
Single-copy gene insertion experiments [20] demonstrated that the Bristol variant can fully res-
cue an amx-2 deletion allele, while insertion of the Hawaii locus had no significant effect in this
assay, indicating that amx-2 activity in the Hawaii background is severely reduced or
even absent.
The identification of a monoamine oxidase as a negative regulator of RAS/MAPK signaling
was initially a surprising result, since MAOA is primarily known for its role in degrading neu-
rotransmitters in the nervous system [12]. However, we observed strong AMX-2 expression in
non-neuronal tissues, especially in the intestinal cells. The 5-HT metabolites such as 5-HIAA
that result from AMX-2 catalysis are likely to be released into the body cavity in order to mod-
ulate RAS/MAPK signaling in distant organs. Such a globally acting regulatory mechanism
may be useful to rapidly adjust RAS/MAPK signaling in response to changing environmental
conditions, after food intake and to adapt the speed of reproduction [36]. Epistasis analysis by
applying exogenous 5-HIAA points at a step downstream of RAS and upstream of MAPK that
is repressed by 5-HIAA. Hence, 5-HIAA may simultaneously repress the RAS/MAPK pathway
activated by various receptor tyrosine kinases in different tissues [4]. The observation that
5-HT exerts an inhibitory effect even in amx-2(0)mutants may be explained by the presence of
additional redundant MAOs, notably AMX-1, and by spontaneous oxidation of 5-HT. Our
epistasis analysis further indicates that 5-HIAA acts via the SER-1 receptor, which activates the
EGL-30 Gqα signaling pathway [31]. One possible scenario is that 5-HIAA and 5-HT exert op-
posing effects on SER-1, such that the balance between 5-HT and 5-HIAA levels determines
the strength of EGL-30 activation, which in turn promotes RAS/MAPK signaling. In line with
this model, Moghal et al. [37] have previously shown that egl-30 signaling in neuronal cells pos-
itively regulates vulval induction under different environmental conditions.
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The role of 5-HT as a neurotransmitter in the mammalian nervous system is well docu-
mented [12]. However, over 90% of the 5-HT in the human body is found outside of the ner-
vous system, especially in enterochromaffin cells of the intestine [38]. Remarkably, Rybaczyk
et al. [39] reported that the expression of the human 5-HT degrading enzyme MAOA, the clos-
est AMX-2 homolog, is consistently down-regulated across many human tumor types. The
functional implications and mechanisms of reduced MAOA expression in cancer cells are un-
clear. Our findings that systemic application of the 5-HT metabolite 5-HIAA globally inhibits
RAS/MAPK signaling may explain the physiological consequences of MAOA down-regulation.
Tumors expressing low levels of MAOAmay generate less oncostatic 5-HIAA and at the same
time contain higher levels of 5-HT, which can promote tumor growth and survival via cross-
talk to the RAS/MAPK pathway [40,41]. Thus, MAOA levels may set a global threshold for the
activation of the RAS/MAPK cascade by different extracellular signals. To our knowledge,
5-HIAA is the first endogenous small molecule that acts as a systemic inhibitor of the RAS/
MAPK pathway.
Materials and Methods
General methods and strains used
Strains were maintained on NGM agar seeded with OP50 bacteria at 20°C [42], unless other-
wise stated. C. elegans Bristol refers to the wild-type N2 strain and Hawaii to CB4856 [8].
Transgenic lines were generated as described in [32,43].
Mutations used
LG I: amx-2(ok1235), egl-30(tg26) [31]; LG II: let-23(sa62)[21], let-23(sy1) [44], tph-1(n4622)
[29]; LG IV: let-60(ga89) [32], let-60(n1046) [7], let-60(n2021) [7], lin-1(n304) [45]; LG V: rde-
1(ne219) [46] LG X: ser-1(ok345) [47]. Transgenic strains: rde-1(ne219); duIs[Pelt-2::rde-1(+);
pRF4] [23], let-60(n1046); rde-1(ne209); zhEx418[Plin-31::rde-1(+); myo-2::mCherry] [24],
gaIS37[HS-mpk-1, dmek] [27], let-60(n1046); saIS14[lin-48p::gfp] [34], zhEx533[Pamx-2::gfp,
Pmyo-2::mcherry], amx-2(ok1235); zhSi73[amx-2 Bristol]; let-60(n1046gf); zhSi74[amx-2 Ha-
waii]; let-60(n1046gf) (all this study).
Generation and genotyping of let-60(n1046)miRILs and Ils
miRILs were generated by crossing CB4856 males with MT2124(let-60(n1046)) hermaphro-
dites. In the F2 generation, lines homozygous for the n1046 allele were singled out and allowed
to self-fertilize for 10 more generations to reach homozygosity by random cloning of individu-
als. At generation F12, lines were regarded as isogenic and frozen for long-term storage. All
228 miRIL lines were genotyped with the following 72 FLP markers as described in [15]: zh1-
17; zh1-10a; zh1-07; zh1-18a; zh1-03; zh1-27; zh1-34; zh1-01;zh1-23; zh1-15; zh1-08; zh1-06;
zh2-04a; zh2-16; zh2-07; zh2-13; zh2-19; zh2-02; zh2-20; zh2-25; zh2-27; zh2-09; zh2-10; zh2-
12; zh3-17a; zh3-07; zh3-06; zh3-08; zh3-28; zh3-15; zh3-04; zh3-02; zh3-05a; zh3-35; zh3-10a;
zh3-11; zh3-13; zh4-04a; zh4-5; zh4-06; zh4-16; zh4-08; zh4-17; zh4-18; zh4-19; zh4-20; zh4-21;
zh4-12; zh5-13; zh5-03a; zh5-14; zh5-05; zh5-16; zh5-17; zh5-18; zh5-11; zh5-12; zh5-08; zh5-
21/22; zh5-09zhX-17; zhX-08; zhX-13; zhX-15; zhX-10; zhX-24; zhX-07; zhX-12; zhX-11; zhX-
21a; zhX-06; zhX-23. miRILs that contained a 100% Bristol genotype and miRILs lacking the
n1046 allele were excluded from further analysis, and miRIls with identical genotypes were
combined. These criteria reduced the 228 initial miRILs to 173 informative lines. To generate
ILs in the n1046 background, the ewIR ILs from [14,17] were crossed with the MT2124(let-60
(n1046)) mutant. For the exact breakpoints of the ILs used, see [17]. FLP mapping with 7 to 8
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markers in the respective regions was used to identify and verify lines homozygous for the in-
trogressions and exclude the presence of additional recombination events. Control siblings
without an introgression were isolated in parallel, and the multivulva phenotype was used to
identify homozygous let-60(n1046) lines. To quantify the VI, at least three independent intro-
gression lines were compared to three sibling lines containing the let-60(n1046) allele but
no introgression.
Phenotyping
To measure the VI, vulval induction was scored in L4 larvae using Nomarski optics as de-
scribed [48], and the average number of induced VPCs per animal was calculated. The duct cell
duplication phenotype was scored using the lin-48::gfpmarker to visualize the duct cells using
fluorescence microscopy [34]. The oocyte maturation phenotype was scored in 2 day old adults
under Nomarski optics microscopy.
QTL mapping and data storage
QTL mapping was performed using a single marker model on the per miRIL averages. Signifi-
cance threshold was estimated using 1000 permutations [14]. All QTL data, phenotypes, QTL
profiles and genotypes are stored in www.WormQTL.org [49].
RNA interference
Gene knock-down was carried out using RNAi feeding according to [18]. For intestine-specific
RNAi, OLB11(rde-1(ne219); duIs[Pelt-2::rde-1(+); pRF4]) [23] was crossed with the MT2124
(let-60(n1046)) strain. For vulva-specific RNAi, the strain AH2927(rde-1(ne219lf); let-60
(n1046); zhEx418[Plin-31::rde-1; Pmyo-2::mcherry]) described in [24] was used.
Generation of single-copy insertion lines
A 7.8 kb genomic fragment spanning the entire amx-2 locus was amplified with the primers
OTS123 (GATTTTGGAGAAGAAACGAGGG) and OTS124 (ACTTCACTATGTTCCTCT
ACCG) using either Bristol or Hawaii genomic DNA as template and subcloned into the XhoI
restriction site of pCFJ151 [20]. Single-copy insertions of the amx-2 Bristol and amx-2 Hawaii
containing plasmids into the ttTi5605 region on chromosome II were generated using the pro-
tocol by [20] to yield zhSi73 and zhSi74, respectively. The insertions were verified by PCR am-
plification using primers flanking the insertion site before crossing them into the amx-2(lf); let-
60(gf) background. For each genotype, at least three independent lines were scored.
Transcriptional amx-2 reporters
Primers OTS219 (AAA AGG ATC CTT AGG TTT ATT GCT GGA AAA AT) and OTS220
(AAA AGG ATC CCC TTA ACC AAA TTT CAT ACC C) were used to amplify 4kb of up-
stream promoter region. The PCR fragment was further cloned into the BamHI restriction site
of pPD95.67 to generate a the Pamx-2::gfp transcriptional reporter plasmid that was co-injected
at 50ng/μl with 2.5ng/μl of the pharyngeal Pmyo-2::mcherrymarker.
Measurement of 5-HT levels
Animals were grown in 100ml liquid cultures and harvested by flotation on 50% sucrose.
Worm pellets were resuspended in 2ml PBS buffer and lysed using a swing-mill homogenizer
followed by high-speed centrifugation to remove insoluble debris. Total protein concentrations
were measured in each sample using the amidoblack staining assay [50]. 5-HT levels were
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determined with an ELISA kit according to the manufacturer’s instructions (BA E-5900, Labor
Diagnostika Nord) and normalized to the total protein concentrations in the extracts. The av-
erage 5-HT concentrations for each genotype were determined with two separate measure-
ments, each done in triplicate using extracts obtained from two independently grown cultures.
Treatment of C. elegans with 5-HT and its metabolites
Standard NGM plates were supplemented with the indicated concentrations of serotonin
(5-HT) (H9523, Sigma), 5-Hydroxyindoleacetic acid (5-HIAA) (H8876, Sigma), dopamine
(DA) (H8502, Sigma) or Melatonin (MT) (M5250 Sigma) and kept in dark at 4°C prior to use.
Quantification of ERK phosphorylation
Phospho MPK-1 levels in total extracts of C. elegans L4 larvae were determined by Western
blotting as described in [11]. As loading controls, total MPK-1 levels were quantified on paral-
lel blots loaded with the same amounts of protein (20μg) from the identical samples. Protein
bands were quantified using the integrated density function in ImageJ. The ratios of phospho-
MPK-1 to total MPK-1 levels were calculated for each extract and normalized to the ratios in
untreated controls. Antibodies used: anti-MAP Kinase (Sigma-Aldrich, M5670), anti-phospho-
MAP Kinase, Activated (Diphosphorylated ERK-1&2, Sigma-Aldrich, M8159).
Supporting Information
S1 Fig. QTL effect sizes. In each of the panels showing chromosomes I through X, the QTL ef-
fect sizes were plotted along the chromosomal locations as shown in Fig 1D. Positive values in-
dicate regions where the Bristol genotype increases and and negative values where the Bristol
genotype decreases the VI.
(JPG)
S2 Fig. Fine-mapping of the QTLs shown in Fig 1D with ILs. ILs covering the predicted QTL
regions were chosen from [17] and crossed with the let-60(n1046) Bristol mutant. Significant
differences in the VI indices between sibling lines with and without introgression were used to
verify and further refine the different QTL regions. Several overlapping introgression lines al-
lowed us to further narrow down the genomic intervals for further studies. The sizes and ap-
proximate positions of the ewIR introgressions are depicted below. For the exact locations of
the breakpoints in each IL, see [17]. Error bars indicate the standard error of the mean, and 
indicates p<0.001 in a Student‘s t-test.
(JPG)
S3 Fig. Sequence similarity between the catalytic domains of AMX-2 and mammalian
monoamine oxidases. The catalytic domain of C. elegans AMX-2 (NP_493236) is most similar
to mammalian MAOA (NP_000231), MAOB (AAH22494) and LAAO (NP_690863). The C.
elegans genome encodes another five putative monoamine oxidase genes, amx-1
(NP_497772.2), amx-3 (NP_001256963), hpo-15 (NP_504456.1), lsd-1 (NP_510000) and spr-5
(NP_493366.1), that are more distantly related to mammalian monoamine oxidases.
(JPG)
S4 Fig. Coding polymorphisms between C. elegans Bristol and Hawaii AMX-2. Structure of
the AMX-2 protein. The blue box indicates the conserved catalytic amine oxidase domain.
Coding polymorphisms are found mainly in the C-terminal region of the protein (R521G,
T532S, N535S and L617P). Only two non-synonymous polymorphisms (V410I and N461S)
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affect the catalytic amine oxidase domain.
(JPG)
S5 Fig. Effects of 5-HT and 5-HIAA on the egg laying rate in liquid. Egg laying rates of one
day-old adults were determined in liquid as described in [30]. For each genotype and condition,
in total 48 animals were assayed in four independent experiments and the average egg laying
rates per animal are shown. Error bars indicate the standard error of the mean,  indicates
p<0.01,  p<0.05 and n.s. p>0.1 in a Student’s t-test.
(JPG)
S1 Table. Estimated QTL effect sizes in additive and interactive mapping models.
(PDF)
S2 Table. Results of the RNAi screen in the QTL1b region. Rows highlighted in green indi-
cate allele-specific effects in the Bristol background, rows highlighted in blue indicate allele-
specific effects in the Hawaii background, and rows highlighted in beige allele-independent ef-
fects. 1SE indicates the standard error of the mean. 2p-values compared to empty vector con-
trols were determined with a Student’s t-test.
(PDF)
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